SuperworthNeurocrine Biosciences NBIX
- Market cap
- $14.5B
- PE
- 20.9×
- 8y median 42.8×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 4.3×
- EV/EBIT
- 18.2×
- Revenue, 12 months
- $3.4B
- +34% on a year ago
- Net margin
- 20.9%
- Free cash flow yield
- 6.0%
Neurocrine Biosciences trades at 20.9× trailing earnings, cheaper than 95% of the last ten years. Revenue was $3.4B over the last twelve months, up 34% on a year earlier with a 21% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $498.8M+29% | $515.2M+25% | $515.3M+23% | $590.2M+30% | $622.1M+25% | $627.7M+22% | $572.6M+11% | $687.5M+17% | $794.9M+28% | $805.5M+28% | $814.5M+42% | $959M+40% | |
| Cost of revenue | $11.2M+84% | $8.5M+10% | $7.5M−12% | $9.2M−20% | $8M−29% | $9.3M+9% | $9.2M+23% | $10.3M+12% | $14M+75% | $17.6M+89% | $13.8M+50% | $23.2M+125% |
| Gross profit | $487.6M+28% | $506.7M+25% | $507.8M+23% | $581M+32% | $614.1M+26% | $618.4M+22% | $563.4M+11% | $677.2M+17% | $780.9M+27% | $787.9M+27% | $800.7M+42% | $935.8M+38% |
| R&D | $142.2M+32% | $137.5M+17% | $159.4M+14% | $191.1M+31% | $195M+37% | $185.6M+35% | $263.2M+65% | $244.3M+28% | $250M+28% | $258.2M+39% | $296.2M+13% | $326.7M+34% |
| SG&A | $204.2M+10% | $218.9M+20% | $243.1M+0% | $242M+9% | $234.3M+15% | $287.8M+32% | $276.5M+14% | $286.3M+18% | $291.6M+25% | $301.8M+5% | $318.5M+15% | $439.7M+54% |
| $141.2M+61% | $150.3M+45% | $99.3M | $145.4M+98% | $183.8M+30% | $142M−6% | $23.6M−76% | $145.6M+0% | $239M+30% | $210.9M+49% | $193.4M+720% | $151.5M+4% | |
| Interest expense | $1.1M−8% | $1.1M+0% | $1.1M+0% | n/a | n/a | n/a | n/a | $0 | n/a | n/a | n/a | $2.9M |
| Pre-tax income | $115.6M+18% | $198.2M+68% | $34.5M | $98.6M−19% | $190.3M+65% | $162.6M−18% | $14.7M−57% | $159.5M+62% | $291.8M+53% | $239.4M+47% | $246.8M+1579% | $162.2M+2% |
| $32.5M+11% | $50.5M+75% | −$8.9M−67% | $33.6M+29% | $60.5M+86% | $59.5M+18% | $6.8M | $52M+55% | $82.3M+36% | $85.7M+44% | $48.9M+619% | $17.8M−66% | |
| Net income | $83.1M+21% | $147.7M+66% | $43.4M | $65M−32% | $129.8M+56% | $103.1M−30% | $7.9M−82% | $107.5M+65% | $209.5M+61% | $153.7M+49% | $197.9M+2405% | $144.4M+34% |
| $0.82+19% | $1.45+65% | $0.42 | $0.63−34% | $1.24+51% | $1.00−31% | $0.08−81% | $1.06+68% | $2.04+65% | $1.48+48% | $1.91+2288% | $1.39+31% | |
| 101.1M+2% | 102.2M+2% | 103.6M+7% | 103.9M+4% | 104.3M+3% | 102.8M+1% | 102.5M−1% | 101M−3% | 102.5M−2% | 104M+1% | 103.4M+1% | 104.2M+3% |
Gross profit: 40 periods, Q2 FY16 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 10 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY14 to Q4 FY21: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Neurocrine Biosciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| NBIXNeurocrine Biosciences | $14.5B | 20.9× | 42.8× | n/m | 4.3× | +34% | 20.9% |
| HALOHalozyme Therapeutics | $14.3B | 37.5× | 21.3× | n/m | 8.6× | +41% | 24.9% |
| EXELExelixis | $16B | 20.3× | 22.8× | n/m | 6.6× | +9% | 35.3% |
| TECHBIO-TECHNE | $11.4B | 63.1× | 61.6× | n/m | 9.4× | −0% | 15.0% |
| RGENRepligen | $10B | 242× | 120× | n/m | 12.7× | +16% | 5.3% |
| KRYSKrystal Biotech | $9.2B | 39.0× | 42.7× | n/m | 20.9× | +23% | 54.8% |
| INCYIncyte | $23.5B | 14.7× | 36.9× | 49.5× | 4.0× | +27% | 27.7% |
| UTHRUnited Therapeutics | $25.2B | 21.0× | 14.1× | 22.0× | 8.0× | +2% | 41.6% |
| ALNYAlnylam Pharmaceuticals | $30B | 37.8× | 69.2× | 26.7× | 6.2× | +95% | 16.8% |
| ONCBeOne Medicines | $42.9B | 67.6× | 68.4× | 48.1× | 7.0× | +34% | 10.7% |
| REGNRegeneron Pharmaceuticals | $82.9B | 19.9× | 19.7× | 12.6× | 5.3× | +9% | 27.9% |
| Peer median | $19.7B | 37.6× | 39.8× | 26.7× | 7.5× | +20% | 26.3% |
More on Neurocrine Biosciences
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #4of 18Biotech stocks with the highest free cash flow yield
- #4of 14Biotech stocks with the fastest earnings growth
- #7of 16Biotech stocks with the lowest PE ratio
- #9of 17Biotech stocks with the lowest EV/EBIT
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .